INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The purpose of this study is to determine whether the combination of two agents, INC280 and bevacizumab, is safe and effective when administered to patients with Glioblastoma Multiforme (GBM) who have progressed after receiving prior therapy or who have unresectable GBM.
Epistemonikos ID: a32803bc0a8ac337329ebe41e2b9ada508689c64
First added on: May 12, 2024